The goal of the research experience in the Urologic Oncology Fellowship is to provide the fellow with skills and experience in cancer biology and laboratory science, which will lead to success in their future academic career.
- In the two-year research track, fellows are encouraged to develop preliminary data and apply for a career development award through the NIH or other agencies to help strengthen chances of early success in an academic career.
Several investigators in the Department of Urology have productive research laboratories and extramural funding. Fellows may choose a research project and mentor from the Department or within the University of Wisconsin Carbone Cancer Center (UWCCC). The Urologic Oncology research space is primarily based within the UWCCC. The UWCCC has a long tradition of excellence in training physicians and PhD investigators and in conducting research in clinical and basic cancer research. As an integral part of the UWCCC, the Department of Oncology (The McArdle Laboratory) is one of the nation’s most respected basic science cancer research facilities. Dr. Harold Rusch, the founder and first director of the McArdle Laboratory, and Dr. Paul Carbone established the UWCCC in the 1970s to foster the development of clinically oriented laboratory and patient research in cancer. As a NCI designated comprehensive cancer center, we believe the UWCCC represents one of the finest clinical and laboratory research centers in the world with almost $150 million in research funding awarded to our 260 members annually.
The urologic oncology faculty is committed to clinical research to improve patient outcomes in cancer surgery. Large developed databases have been established within the Department to help answer important clinical oncology questions and improve patient care. Statistical and research support are available within the department and cancer center.
- Fellows participate in didactic courses in oncology, biostatistics, and ethics as well as weekly multi-disciplinary meetings.
The University of Wisconsin is also home to a School of Public Health and options are available for candidates interested in performing population-based research and obtaining advanced training within those programs.
- An additional research year may also be utilized to obtain a Master’s Degree in Public Health or clinical investigation.
Annually, the Urologic Oncology faculty and fellows present basic and clinical projects at the:
American Urological Association (AUA) annual meeting, Society of Urologic Oncology (SUO) Annual Meeting, American College of Surgeons (ACS) Clinical Congress, Society For Basic Urologic Research (SBUR) Annual Meeting, International Kidney Cancer Symposium, North Central Section AUA Annual Meeting, and ASCO Genitourinary Cancers Symposium.
- Fellows receive funding and are encouraged to present research findings at national meetings.
Selected Recent Publications
|1.||Abel EJ, Wood CG, Eickstaedt N, Fang JE, Kenney P, Bagrodia A, Youssef RF, Sagalowsky AI, Margulis V. Preoperative pulmonary embolism does not predict poor postoperative outcomes in patients with renal cell carcinoma and venous thrombus. J. Urol. 2013 Aug; 190(2):452-7. |
[PubMed ID: 23434945]
|2.||Ewald JA, Downs TM, Cetnar JP, Ricke WA. Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma. PLoS ONE 2013; 8(2):e55414. |
[PubMed ID: 23383328, PMCID: 3562183]
|3.||Desotelle J, Truong M, Ewald J, Weeratunga P, Yang B, Huang W, Jarrard D. CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer. J. Urol. 2013 Jan; 189(1):329-35. |
[PubMed ID: 23174249, PMCID: 3581042]
|4.|| Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin DW, Jarrard DF. Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J. Urol. 2013 Jun; 189(6):2335-41. |
[PubMed ID: 23159584, PMCID: 4226217]
|5.|| Babaian K, Truong M, Cetnar J, Cross DS, Shi F, Ritter MA, Jarrard DF. Analysis of urological procedures in men who died from prostate cancer using a population-based approach. BJU Int. 2013 Mar; 111(3 Pt B):E65-70. |
[PubMed ID: 23130676, PMCID: 4209594]
|6.|| Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis. J. Urol. 2013 Feb; 189(2):422-9. |
[PubMed ID: 23017522, PMCID: 3581046]
|7.||Truong M, Yang B, Wagner J, Kobayashi Y, Rajamanickam V, Brooks J, Jarrard DF. Even-skipped homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence. Br. J. Cancer 2012 Jun 26; 107(1):100-7. |
[PubMed ID: 22596233, PMCID: 3389415]
|8.|| King AC, Livermore A, Laurila TA, Huang W, Jarrard DF. Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer. Urol. Oncol. 2013 Aug; 31(6):739-43. |
[PubMed ID: 21816639, PMCID: 4209721]
|9.||Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur. Urol. 2011 Dec; 60(6):1273-9. |
[PubMed ID: 21784574, PMCID: 4378714]
|10.||Downs TM, Burton DW, Araiza FL, Hastings RH, Deftos LJ. PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3. Cancer Lett. 2011 Jul 01; 306(1):52-9. |
[PubMed ID: 21444150]
|11.|| Abel EJ, Culp SH, Meissner M, Matin SF, Tamboli P, Wood CG. Identifying the risk of disease progression after surgery for localized renal cell carcinoma. BJU Int. 2010 Nov; 106(9):1277-83. |
[PubMed ID: 20394619]
|12.|| Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur. Urol. 2011 Jan; 59(1):10-5. |
[PubMed ID: 20952123, PMCID: 4378833]
|13.||Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J. Urol. 2010 Nov; 184(5):1877-81. |
[PubMed ID: 20850148, PMCID: 4809737]
|14.||Bibikova M, Chudin E, Arsanjani A, Zhou L, Garcia EW, Modder J, Kostelec M, Barker D, Downs T, Fan JB, Wang-Rodriguez J. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics 2007 Jun; 89(6):666-72. |
[PubMed ID: 17459658]
|15.|| Luo Y, Chen X, Downs TM, DeWolf WC, O’Donnell MA. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J. Immunol. 1999 Feb 15; 162(4):2399-405. |
[PubMed ID: 9973521]
|16.||Downs TM, Szilvasi A, O’Donnell MA. Pharmacological biocompatibility between intravesical preparations of BCG and interferon-alpha 2B. J. Urol. 1997 Dec; 158(6):2311-5. |
[PubMed ID: 9366382]